XOMA Corporation
http://www.xoma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From XOMA Corporation
Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?
Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.
Torrent Spells Out Ambitions For $300m Business In The US
India’s Torrent underlined that it had no plans of decreasing its commitment to the US market, while plotting continued growth in India and Germany, as it delivered financial results for its 2023/24 financial year.
Company Information
- Industry
- Miscellaneous
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Enumeral Biomedical Inc.
- XOMA Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice